Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. by Sloan, Melanie et al.
Original article
Medically explained symptoms: a mixed methods
study of diagnostic, symptom and support
experiences of patients with lupus and related
systemic autoimmune diseases
Melanie Sloan1, Rupert Harwood2, Stephen Sutton1, David D’Cruz3,
Paul Howard4, Chris Wincup 5, James Brimicombe1 and Caroline Gordon6
Abstract
Objectives. The aim was to explore patient experiences and views of their symptoms, delays in di-
agnosis, misdiagnoses and medical support, to identify common experiences, preferences and unmet
needs.
Methods. Following a review of LUPUS UK’s online forum, a questionnaire was posted online during
December 2018. This was an exploratory mixed methods study, with qualitative data analysed themati-
cally and combined with descriptive and statistically analysed quantitative data.
Results. There were 233 eligible respondents. The mean time to diagnosis from first experiencing
symptoms was 6 years 11 months. Seventy-six per cent reported at least one misdiagnosis for symp-
toms subsequently attributed to their systemic autoimmune rheumatic disease. Mental health/non-
organic misdiagnoses constituted 47% of reported misdiagnoses and were indicated to have reduced
trust in physicians and to have changed future health-care-seeking behaviour. Perceptions of physi-
cian knowledge and listening skills were highly correlated with patient ratings of trust. The symptom
burden was high. Fatigue had the greatest impact on activities of daily living, yet the majority
reported receiving no support or poor support in managing it. Assessing and treating patients holisti-
cally and with empathy was strongly felt to increase diagnostic accuracy and improve medical
relationships.
Conclusion. Patient responses indicated that timely diagnosis could be facilitated if physicians had
greater knowledge of lupus/related systemic autoimmune diseases and were more amenable to listen-
ing to and believing patient reports of their symptoms. Patient priorities included physicians viewing
them holistically, with more emotional support and assistance in improving quality of life, especially in
relation to fatigue.
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Introduction
SLE is a chronic, inflammatory, autoimmune disease,
which can be life threatening. With no definitive diagnos-
tic tests for SLE and related diseases and with a diver-
sity of often non-specific presenting symptoms [1],
patients are largely reliant upon expert medical opinion
for a diagnosis, with delays in diagnosis and subsequent
treatment commonly reported [2–4]. Multiple studies in-
dicate weaknesses in how medical training addresses
SLE and other rheumatological conditions [5–8] and
highlight a need for greater awareness amongst clini-
cians in order to aid faster diagnosis [9]. In addition,
there have been calls for more patient-focused
research [2].
The problem of undiagnosed lupus in the community
was recognized >20 years ago [10]. Despite attempts to
increase awareness of the disease, more recent studies
report lengthy journeys to diagnosis [2–4], with many
patients having accrued considerable damage to their
health by the time they reach diagnosis and with earlier
treatment being associated with better prognosis [11–
13]. A 2014 survey of >2500 LUPUS UK members found
that the mean time to diagnosis from initial symptom
awareness was 6.4 years, with approximately half report-
ing that they were initially misdiagnosed [2]. Diagnostic
delays of >3 years were also reported by 58% of lupus
participants in the 2017 Rare Autoimmune Rheumatic
Diseases Alliance (RAIRDA) survey [4].
Guidance for UK practitioners was lacking until the
publication of the British Society for Rheumatology
guideline for the management of lupus in 2017 [14].
Research on patient experiences and preferences is key
to increasing the impact of the guideline, because diag-
nosis and effective disease management is likely to be
influenced strongly by patient–physician interactions.
There has been important patient perspective re-
search in recent years, including research reporting on
access to health care, diagnostic delays and the fre-
quency of misdiagnoses [2–4, 9]. However, significant
gaps in the literature remain, particularly with regard to
ascertaining patient views of the reasons for, and
impacts of, diagnostic delays and misdiagnoses. In this
study, we address these gaps and investigate patient
perceptions of their symptoms, support received from
clinicians and patient suggestions for improvements in
diagnosis and care.
Methods
Data collection
After a review of patient priorities on the LUPUS UK
Web-based forum and discussions with patients,
LUPUS UK and rheumatologists, a questionnaire (sup-
plementary material, section Questionnaire, available at
Rheumatology Advances in Practice online) was
designed to collect quantitative and qualitative data. The
main survey sections included: perceptions of support,
symptoms, and reasons for misdiagnoses/delays. Open
questions to elicit qualitative responses covered: mis-
diagnosis experiences, advice to doctors on improving
diagnosis and care, and an invitation at the end of the
questionnaire to give any further patient views. The
questionnaire was pre-tested and then made available,
with an accompanying information sheet, for 3 weeks in
December 2018 for completion online using Qualtrics,
on the LUPUS UK online forum and Lupus UK sufferers
Facebook group. The supplementary material section
Methodology, available at Rheumatology Advances in
Practice online, provides a more in-depth description of
data collection, analysis and study limitations. This study
complies with the Declaration of Helsinki. The
Cambridge psychology research ethics committee ap-
proved the research [PRE 2018–84], and informed con-
sent was obtained from all respondents.
Inclusion criteria were as follows: age 18 years;
reporting a diagnosis of lupus, UCTD, MCTD, SS or
overlap condition on their clinic letters; and listing symp-
toms that were supportive of these diagnoses, including,
in the case of those reporting a diagnosis of SLE, symp-
toms that were supportive of a diagnosis made in line
with the ACR and/or SLICC classification criteria [15,
16]. The 2% reporting probable lupus were also in-
cluded, because their reported symptoms met the
criteria.
Analysis
After data cleaning and removal of ineligible participants,
quantitative data from 233 participants were analysed
using SPSS v.25. Qualitative responses were provided
by 182 respondents on the questionnaire, with a further
24 providing information by contacting the research
team.
Qualitative data were combined and analysed themat-
ically [17] using NVivo v.12 to assist with coding and
classification. Briefly, analysis involved: immersion in the
Key messages
. Diagnostic delays and misdiagnoses are common in SLE/CTD and can damage trust in physicians.
. SLE/CTD patients strongly value physicians taking a holistic view, listening, and believing patient-reported
symptoms.
. More support is required with adapting after SLE/CTD diagnosis and in improving quality of life.
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data; developing and agreeing an initial coding scheme;
coding the data; refining and re-coding; and identifying
commonly occurring themes [17]. Once provisional
themes had been identified, the LUPUS UK forum mod-
erator (P.H.) posed several questions [18–20] to the on-
line community to confirm that emerging themes
reflected the wider community views and to allow the
lead researcher (M.S.) to probe responses in more
depth. Validity of the findings was also strengthened by
member checking [21, 22], comparing emerging themes
with forum discussions and examining deviant cases
[23]. Further triangulation occurred by the integration of
qualitative and quantitative data [24, 25].
Results
Areas identified from thematic analysis to improve diag-
nosis and care were as follows: the importance of listen-
ing and belief; holistic viewpoint; and knowledge
acquisition and transfer.
Participants
Participant characteristics are shown in Table 1. There
were 78% of respondents reporting a diagnosis of SLE,
10% with UCTD, and 12% with other related autoim-
mune conditions. The vast majority of respondents were
white and female, and 70% were resident in England.
Delays and misdiagnoses
The average time to diagnosis from first experiencing lu-
pus/CTD symptoms was 6 years 11 months (mean) and
4 years (median), with 24% of respondents reporting
that diagnosis took >10 years and 22% reporting that
they were diagnosed within 1 year. At least one misdiag-
nosis was reported by 76% of respondents, with 47%
of all misdiagnoses being of non-organic aetiology, psy-
chological, mental health (MH) or medically unexplained
symptoms (MUS), with the combined category referred
to henceforth as MH/MUS. Misdiagnoses were most fre-
quent amongst respondents with UCTD, with 95%
reporting receiving one or more.
Misdiagnoses are summarized in Fig. 1, with health
anxiety being the most frequent, followed by misdiagno-
ses of alternative rheumatic diseases, most commonly
RA.
More than 80% of the respondents who reported re-
ceiving a MH/MUS misdiagnosis (often referred to by
participants and forum members as an ‘in your head’
misdiagnosis) indicated that it had both reduced their fu-
ture trust in physicians and altered their health-care-
seeking behaviour, with the impact of these misdiagno-
ses illustrated in the following quote:
The misdiagnosis of stress, unexplained etc. is the most dangerous
misdiagnosis and it completely destroys trust, feels like you are not
being listened to, like you are explaining it wrong, doing something
wrong, doing this to yourself and it causes guilt, mistrust and
makes you question yourself (female, 30s, England).
The majority (60%) of respondents reported that these
MH/MUS misdiagnoses had made them less likely to
seek medical help and report symptoms in the future.
For others (27%), these misdiagnoses made them more
likely to seek help, often detailing how they ‘knew’ their
‘own bodies’ and continued to seek clarity for continuing
symptoms in the face of medical disbelief in an organic
aetiology.
Table 2 summarizes patient views of the key influen-
ces on delays and misdiagnoses. The most commonly
experienced symptoms before diagnosis were often
non-specific (rashes, fatigue, joint pain and oral ulcers)
and difficult to attribute to a single disease unless
viewed in the context of a systemic illness.
Patients reporting atypical serology, especially perma-
nently negative ANA, experienced much greater diag-
nostic delays (mean delay of 13 years for permanently
ANA-negative participants) than ANA-positive patients,
with 92% (exact binomial 95% CI: 62%, 100%) of sero-
negative respondents taking >4 years to be diagnosed,
compared with 55% (95% CI: 44%, 66%) with positive
ANA and 65% (95% CI: 48%, 78%) with intermittently
positive ANA. No seronegative participants were diag-
nosed within 1 year, compared with 26% of ANA-posi-
tive patients (95% CI: 17%, 37%). Using Fisher’s exact
test between seronegative, ANA intermittently positive
and ANA-positive groups, there was a significant differ-
ence (P¼ 0.0386) in the percentages taking >4 years to
be diagnosed.
Multiple participants who lacked visible symptoms
and/or consistent positive serological markers com-
mented on the sense of invalidation and physician dis-
belief when test results did not reflect the severity of
their symptoms, as articulated by this participant:
The rheumatologist sent me to see a psychiatrist because I com-
plained that I felt ill even though the blood results were OK. The
previous results were positive. Psychiatrist said that I was OK and I
should get a new rheumatologist who knew more about lupus (fe-
male, 50s, England).
Additional evidence of the greater diagnostic/care diffi-
culties experienced by the permanently ANA-negative
group was their very high rate of MH/MUS misdiagnoses
(92%). However, those reporting positive anti-dsDNA
still had a mean diagnostic delay of 6 years 2 months,
and 54% reported an MH/MUS misdiagnosis.
Missed diagnosis and misdiagnoses after diagnosis
A quarter of participants felt that diagnoses provided for
new symptoms arising post SLE diagnosis were incor-
rect. A quarter of these perceived that they were mis-
diagnosed with fibromyalgia; 25% with anxiety or MH
issues; and 8% with functional disorders, either gastro-
intestinal or neurological; and, as instanced in the fol-
lowing quote, many participants had been subject to
multiple misdiagnoses:
Myriad of patronising psychological assumptions, including health
fixation disorder, anxiety and fibromyalgia. All while flaring with
eventual proven pathology (female, 50s, Australia).
Medically explained symptoms in SLE and CTD
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Other participants expressed concern that new symp-
toms were attributed too quickly to their SLE, with other
potential causes not appropriately investigated, as this
participant details:
I had to have my gall bladder removed quite suddenly and my GP
[general practitioner] had been telling me that lupus caused diges-
tive problems so didn’t investigate it (female, 30s, England).
Conversely, this participant, in common with others,
reported feeling that some symptoms were not correctly
attributed to the disease, leading to greater anxiety over
the possible aetiology:
Not understanding what is happening to your body is distressing
and scary. One of the symptoms I have (difficulty swallowing food/
choking) has never been connected to lupus, but I am sure this is
the case (female, 60s, England).
Symptoms, serology and disease burden
As Fig. 2 demonstrates, the symptom burden was high.
Fatigue was reported to be present all or most of the
time by 82% of respondents and specified by the major-
ity to be the symptom impacting their life the most, fol-
lowed by pain, then cognitive dysfunction. The
invisibility of these symptoms to society and physicians
generates an additional challenge of feeling ‘disbe-
lieved’, as highlighted by this respondent:
The fatigue and the pain really is life changing. It’s not easy to see,
but it’s there and very real (female, 30s, England).
Interestingly, only 3% of patients responded that organ
involvement had the most significant impact, including
those with lung, heart, brain or kidney involvement, who
predominantly also considered fatigue or pain to be
most impactful.
The life-changing impact of these multiple, largely in-
visible symptoms was highlighted by many, including
the reduction in physical and cognitive abilities; greatly
reduced quality of life; and the impact on families, social
life and employment. The majority (77%) had stopped
TABLE 1 Participant characteristics (n¼233)
Characteristic Number Percentage
(rounded)
Diagnosis on clinic letters
SLE (may have listed addi-
tional diagnosis)
181 78
Undifferentiated or unspeci-
fied CTD
23 10
APS or overlap syndrome 8 3
SS 7 3
Discoid or cutaneous lupus 5 2
Probable lupus 5 2
MCTD 4 2
Country of residence
England 163 70
Scotland 33 14
Wales 20 9
USA/Canada 7 3
Australia 5 2
Mainland Europe 4 2
Northern Ireland 1 <1
Time delay to diagnosis
<1 year 52 22
1–3 years 42 18
4–9 years 46 20
10þ years 57 24
Unsure or non-quantitative
response
30 13
Missing 6 3
Age band (years)
18–29 18 8
30–39 30 13
40–49 59 25
50–59 69 30
60–69 32 14
70þ 7 3
Missing 18 8
Ethnic group
White 193 83
Mixed 4 2
Asian 2 1
Black or African American 1 <1
Other 1 <1
Missing 32 14
Gender
Female 199 85
Male 7 3
Prefer not to say 1 <1
Missing 26 11
Education
None 2 1
GCSE/O level 37 16
A level 55 24
Degree 68 29
Postgraduate 36 15
Missing 35 15
Medications (current or within
the last year)
(continued)
TABLE 1 Continued
Characteristic Number Percentage
(rounded)
HCQ 143 72
Oral CSs 96 48
Immunosuppressant (MMF,
AZA or MTX)
85 43
Injected CSs 52 26
Biologics 12 6
CSA or tacrolimus 7 4
CYC 6 3
Percentage currently taking
at least one of the above
medications ¼ 91%
Note that medication percentages are calculated from
those reaching that part of the questionnaire (198
participants).
Melanie Sloan et al.
4 https://academic.oup.com/rheumap
working, reduced hours or changed jobs at some stage
as a result of their disease, with 34% of participants not
currently working because of their health issues.
Support
Fig. 3 displays that approximately half of respondents per-
ceived that they were receiving good or excellent support
overall and from their rheumatologist. Mean scores (1–5,
with 1 being no support to 5 being excellent support) for
overall support were less for UCTD (2.6) and patients in
Wales (2.7), and slightly higher for anti-dsDNA-positive
participants (3.5), than the overall mean (3.3).
The need for much greater support with adapting,
accepting and coping mentally with the disease was
supported by the qualitative findings and was a key ele-
ment of the identified holistic viewpoint theme. This
theme encompasses the indicated patient belief that
physicians should improve diagnosis by viewing symp-
toms together and should improve treatment by provid-
ing care for every aspect of the patient affected by the
disease. It was commonly expressed that this care
should include more support and empathy; consider-
ation of mental in addition to physical health; and help
with improving quality of life and with learning to live
with a life-changing disease. Aspects of this theme are
reflected in the following participant quote:
I have treatment for the disease but not as a person who has lost
so much. It’s a devastating illness.. . . Delays in diagnosis are
damaging physically and mentally. There is a clear pattern of grief,
coming to terms with a massive loss of quality of life. I’ve had no
emotional support (female, 40s, England).
Clinician support: knowledge, trust and listening skills
Respondents were asked to rate the different types of
clinicians they had consulted for their SLE/CTD for
listening skills, knowledge of lupus and the level of trust
the patient felt for that type of doctor. The options pro-
vided were very poor, poor, moderate, good or very
good.
Clinicians consulted by >15% of respondents included
(in descending order of quantity consulting) GP, rheuma-
tologist, lupus specialist, accident and emergency (A&E)
doctor, specialist nurse, physiotherapist, neurologist, der-
matologist, cardiologist, nephrologist, psychologist/coun-
sellor, haematologist and immunologist.
The ratings for non-rheumatology specialists were
analysed separately by speciality, but were largely simi-
lar so were combined in Fig. 4, with any significant dif-
ferences reported individually.
The clinicians considered to have the poorest knowl-
edge of lupus were A&E doctors, GPs and neurologists,
with respective ratings for poor/very poor knowledge
being 66, 50 and 51%.There was a mean of 36% poor/
very poor ratings for the knowledge of all specialist
physicians, excluding rheumatology clinicians.
Knowledge acquisition and exchange was a major
theme identified. Knowledge acquisition by physicians
was felt to be of prime importance for diagnosis,
whereas knowledge exchange becomes a patient prior-
ity post-diagnosis. This theme included patients wanting
physicians to provide them with more information, espe-
cially at the diagnostic appointment. It also included
physicians being more amenable to patients sharing
their (often extensive) knowledge of the disease and
their individual manifestations. The importance of physi-
cians admitting limited disease-specific knowledge and
referring more quickly for appropriate testing and con-
sultations with specialists was also identified within this
theme. Many patients reported feeling that MH/MUS
misdiagnoses were attributable to lack of knowledge by
the physician of immune dysfunction and not listening
to/believing a patient’s symptoms.
FIG. 1 Types and rates of misdiagnoses in order of decreasing frequency n¼ 156 reporting a misdiagnosis from
n¼205 participants reaching this section of the questionnaire.
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Trust was highest in lupus specialists, specialist
nurses and physiotherapists. For all physician catego-
ries, trust exhibited a strongly positive correlation with
both perception of listening skills (mean r¼ 0.83) and
knowledge (mean r¼ 0.79). The correlation between
trust and knowledge was lowest for psychologists
(r¼0.58) and GPs (r¼ 0.72). Several participants
reported that their expectations of knowledge in these
clinicians is not high, but that they valued their support
and listening skills. One participant, for example, wrote:
I have a very amazing GP; she listens to me each time I see her. I
guess it can be harder for GPs to have the full knowledge as they
see so many illnesses on a daily basis. For me, just being listened
to is a good feeling. My GP cannot fix me but she has really helped
me so much in this battle (female, 30s, England).
Most clinicians, including rheumatologists, had 30% of
ratings in the poor/very poor categories for listening, with
the exception of lupus specialists, immunologists and
specialist nurses, who received fewer ratings of poor/very
poor (16–20%), and A&E doctors, who received the most
poor/very poor ratings for listening (56%).
The overarching qualitative theme was the importance
of listening and belief in patient symptom reporting, in
terms of being essential in linking multiple diverse symp-
toms for a quicker diagnosis and identifying flares, in
validating the subjective experiences of patients and
TABLE 2 Participants’ views of reasons for delays/misdiagnoses
Perception of reason for delays/
misdiagnosis
Percentage of participants
indicating likely/very likely
that this had contributed to
their delay/misdiagnosis
Example quotes from qualitative responses
The doctor/s initially seeing and treat-
ing each symptom separately and
not linking together as one disease
80 I used to go in with a long list of medical issues
that screamed of APS/lupus/Sjo¨gren’s, but not
one GP joined the dots. Sadly, by the time I was
diagnosed aged 45 it was too late. I’d had a
stroke, DVT [deep vein thrombosis], miscar-
riages and was struggling to work. I wish I’d
been diagnosed earlier and had help so much
sooner (female, 50s, Wales)
Symptoms disregarded or disbelieved
by the doctor/s (merged with the
category of psychological/all in your
head misdiagnoses because the two
were found largely to duplicate)
72 I feel quite upset that I was diagnosed with ‘just
anxiety’ by my GP even to the point where I was
lectured on the ‘worried well’ and prescribed a
book on health anxiety! I read it diligently but,
needless to say, it didn’t make my symptoms
disappear (female, 50s, UK)
I was unsupported for years after a rheumatologist
told me my symptoms were all in my mind and
had I been sexually abused as a child (female,
50s, England)
The doctor/s not having enough
knowledge of the disease (category
merged with those feeling they were
misdiagnosed owing to not having
what doctor/s considered the right
test results or typical symptoms)
69 Neurologist said he didn’t believe in lupus and
consultant rheumatologist was not interested in
discussing symptoms or history as I haven’t lost
my hair, didn’t have a malar rash and I’m male.
Thankfully, he referred me to a lupus specialist
(male, 40s, England)
I was dismissed by rheumatology, having been
told ‘there’s nothing wrong’. This was 7 years
before diagnosis of SLE by blood test. In that
time, I suffered badly, had to reduce working
hours and had long periods of being unable to
work at all. Symptoms can appear long before
markers show in blood (female, 30s, England)
Symptoms appearing slowly over time 59 The symptoms can be confusing; we did not link
my previous symptoms together as I just thought
I was ageing badly (female, 60s, England)
You not reporting or you underplaying
symptoms
39 We underplay our symptoms as we get fed up with
constantly moaning about feeling unwell or rub-
bish (female, 40s, England)
Categories were predetermined from literature review, forum analysis, patient, physician and LUPUS UK input. Five options
were given, ranging from very unlikely to very likely, with this section completed only by participants who considered they
had experienced delays and/or misdiagnosis (n ¼ 175). The seven predetermined questionnaire categories were found to
duplicate responses and were therefore condensed into five categories.
Melanie Sloan et al.
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FIG. 3 Perceived level of support (n¼211) ordered by decreasing level of support
FIG. 2 Patient-reported symptoms and serology n¼ 200. Only respondents stating they had a diagnosis of SLE on
their clinic letters and meeting ACR and/or SLICC criteria were included in the serology categories (self-reported by
those who knew their serological results, e.g. 111 participants for ANA).
Medically explained symptoms in SLE and CTD
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building a supportive relationship with the patient, as
explained by this patient:
He (lupus specialist) said he believed everything I was saying and
asked me what life is like living with this. It was very emotional for
me because I felt listened to (female, 30s, England).
Further sub-themes and patient quotes can be found in
Supplementary Table S1, available at Rheumatology
Advances in Practice online.
Discussion
This mixed methods study identified a number of com-
monly occurring patient experiences, both before and
after a diagnosis of SLE/CTD. As far as we are aware,
this is the first study to ascertain the opinions of SLE/
CTD patients regarding causes of delays/misdiagnoses
and perceptions of support, including impact upon fu-
ture health-care behaviour.
With 76% of respondents reporting at least one mis-
diagnosis and 24% having taken >10 years to reach di-
agnostic certainty, the diagnostic challenges identified
by earlier studies [2–4] remain of key importance to ad-
dress. Although diagnostic difficulties are attributable, in
part, to challenging and varied presentations of the dis-
ease, the importance of listening to and believing
patients is highlighted by this study, with many patients
reporting early symptoms being dismissed and 30% of
all ratings for clinician’s listening skills being in the poor/
very poor categories. Viewing symptoms and patients
holistically and physicians acquiring and sharing knowl-
edge were also key areas identified to improve diagno-
sis and care.
MUS/MH misdiagnoses were reported as damaging
to MH, trust in physicians and health-care-seeking be-
haviour, occurring in almost half of misdiagnosed
participants before diagnosis. This propensity for early
psychological misdiagnosis in systemic autoimmunity is
in line with a recent US study of >3000 SLE patients in
which >50% were initially told there was nothing wrong
or their symptoms were psychological [3]. Misdiagnoses
were also reported to occur after diagnosis with
SLE/overlap disease in 25% of our respondents; these
were largely non-organic pain, fatigue or MH related co-
diagnoses, which respondents and forum members gen-
erally felt were caused by and should be attributed to
their CTD.
Our findings highlight that fatigue is a prevalent and
debilitating symptom, in keeping with a number of previ-
ous studies [2, 9, 26, 27], and remains a problem even
when the disease is not obviously clinically or serologi-
cally active [28]. Despite limited understanding or con-
sensus on mechanisms and an absence of proven
biomarkers [29], fatigue is clearly a major unmet need,
with >70% of participants reporting no support or poor
support with managing fatigue in our study and others
[30]. This affects those with UCTD or non-organ involve-
ment SLE as much as those with severe SLE.
In terms of between-groups differences, participants
with UCTD and participants resident in Wales had the
poorest perception of overall medical support. Great
concerns over local barriers to accessing specialist care
were detailed by those living in Wales.
The first physicians likely to be assessing these
patients are those rated by >50% of patients as having
very poor/poor knowledge of SLE (predominantly GPs
and A&E clinicians), with correct testing, referrals to
specialists and treatment often reported to be delayed.
Many of the patients in this study were disadvantaged
by a presentation of multiple symptoms, multiple sys-
tems, multiple times often being attributed to MH/MUS,
especially if there are no presenting visible symptoms or
organ involvement. Tschudi-Madsen et al. [31] reported
FIG. 4 Patient ratings for clinician knowledge, listening skills and trust (n¼ 206) in order of decreasing patient trust
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that the hypothesis prevalent in current literature is that
multisymptomatology and MUS are closely related and
found a strong correlation between physicians’ assess-
ment of MUS and the number of symptoms reported.
Although it can be difficult for a non-specialist to identify
lupus, and investigating the underlying cause of symp-
toms is often delayed by logistical and time constraints
in primary care and by stringent criteria for referrals,
multiple diverse symptoms should also be considered a
red flag for considering an autoimmune multi-system
disease.
One of the barriers to diagnosis is from physicians
mistakenly considering ANA and anti-dsDNA positivity
as essential for referral to rheumatology/diagnosis, also
sometimes failing to interpret or test for other relevant
haematological or immunological abnormalities, as
specified in the BSR and other guidelines [14–16].
Although self-reported in this study, the 8% of seroneg-
ative and the 32% of SLE patients with a combination of
historical positive and negative ANA results is in line
with expert opinion and recent research findings.
Autoantibody profiles can change over time, can vary in
titre and positivity independent of disease activity, are
heavily influenced by which test individual laboratories
use, can become negative over time/owing to medica-
tion, and symptoms may occur before development of
autoantibodies [32–36]. Although true seronegativity
(permanently negative ANA and anti-dsDNA) is often es-
timated in 5–8% of the SLE population, this includes
only those who have achieved diagnosis. The much
greater diagnostic delay in seronegative patients in this
study (>4 years for 92% compared with 55% for sero-
positivity and 65% for intermittent ANA positivity) was
statistically significant (P¼0.0386) and suggests that the
real percentage is much higher, with many potentially
remaining undiagnosed and untreated.
Despite anti-dsDNA-positive participants having the
most specific biomarker for SLE, they still experienced
considerable diagnostic delay, with a mean time to diag-
nosis of 6 years and 2 months, and with 54% reporting
having received an MUS/MH misdiagnosis. Although
these figures were better than those for permanently se-
ronegative participants (for whom the mean time to di-
agnosis was 13 years, and 92% of whom reported an
MH/MUS misdiagnosis), they still raise the question of
whether there is sufficient knowledge and early testing
of autoantibodies in primary care.
Multiple respondents reported, in common with other
studies, feeling disbelieved when typical serological/
other test results did not reflect their symptoms. There
is a perceived over-reliance on certain test results,
rather than also considering subjective symptoms [37,
38], and a need for more widespread use and under-
standing of a broader range of haematological and im-
munological tests [14]. This study also highlights the
need for more support, empathy and communication in
managing all symptoms, regardless of serology or (often
conflicting and still evolving) views of their aetiology.
Although 50% of respondents reported either good
or excellent support for their lupus overall and from their
rheumatologist, there were common gaps in care identi-
fied. There is a clearly expressed need for more support
for patients in coming to terms with a life-changing
chronic disease and more consideration of psychosocial
needs and quality of life. Empathetic listening and belief
in the patient’s subjective reporting of symptoms was
highlighted as the top patient priority for improvements
for diagnosis and care, yet this aspect of consultations
was often felt to be unsatisfactory in this study and
other studies of rheumatic diseases [39]. Listening was
highly correlated with trust, with positive views being
expressed about physicians, often GPs, who provided
support and compassion despite limited knowledge and
diagnostic uncertainty.
The main limitation of this study was that participants
were not demographically representative of the SLE
population, especially in terms of ethnicity, with patients
of African and Asian origin under-represented, as is
common in rheumatological research [40]. Online sup-
port groups may also not be representative of all
patients in terms of age, education, severity of disease
and satisfaction with medical support because they are
actively seeking more peer support. We will address
these concerns with a prospective clinic-based study in
the future. Although the research and questionnaire
were phrased neutrally, the study might have attracted a
higher proportion of patients with negative experiences.
The responses, including previous symptoms and sero-
logical results, might be subject to recall bias and error
owing to self-reporting. The serological results might be
skewed towards those with abnormal results because
these will have been more likely to be communicated to
patients and be more memorable. Mean diagnostic time
and proportion in the >10 years to diagnosis group are
likely to be greater than reported because >10% of
responses were excluded owing to non-numerical
responses, usually for lengthier time scales (e.g. ‘a long
time’).The assessment of misdiagnoses was from the
viewpoint of the participants. Some respondents might
have had a concurrent MH condition alongside SLE, or
MH symptoms might have been a presenting part of
their unrecognized developing systemic autoimmunity.
Although a limitation is that diagnoses were self-
verified, we mitigated against this by asking for the diag-
nosis on their clinic letters and checking that symptom
lists were indicative of these conditions. A further check
was that 91% of participants were currently taking at
least one medication prescribed to manage SLE and re-
lated conditions. Responses on a questionnaire are less
likely to be subject to social desirability bias and more
open than responses given to physician questioning, es-
pecially regarding the reporting of negative views about
medical care. Analysis of both quantitative and qualita-
tive data allows for greater depth and breadth of under-
standing [24, 25] and increases the validity, reliability
and credibility through the triangulation of results.
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The large number of respondents sending additional
qualitative information and expressing gratitude for a
study that gave them the opportunity to detail their
experiences and opinions demonstrates the importance
of giving patients with chronic diseases a voice. In addi-
tion to the research alerting policy-makers and physi-
cians to common, and possibly avoidable, negative
experiences, whilst gaining insight into best practice, the
further benefits are that many of these patients reported
feeling more empowered and hopeful of improvements
in diagnosis and care for patients in the future from be-
ing involved in the research.
In conclusion, physicians viewing symptoms/patients
holistically and listening to (and believing) patients’
reports of their symptoms is felt to be of prime impor-
tance by patients both in achieving diagnosis and in
managing the disease post-diagnosis. More medical
support could help to improve the reduced quality of
life, especially in relationship to fatigue, where the ma-
jority of participants reported receiving no support or
poor support. Improved knowledge of SLE amongst
GPs and all physicians, regardless of specialism, is re-
quired because the multi-system nature of the disease
necessitates a multi-disciplinary approach.
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